Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.

We developed a xenograft model of human Chronic Eosinophilic Leukemia (CEL) to study disease progression and remission-induction under therapy with tyrosine kinase inhibitors using imatinib and nilotinib as examples. The FIP1L1/PDGFRA+ human CEL cell lineEOL-1 was injected intravenously into scid mi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Daniel Wicklein, Nuno Ramos Leal, Johannes Salamon, Mohammed Thamer, Harald Herrmann, Peter Valent, Udo Schumacher, Sebastian Ullrich
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2cb6ae5dc92e4ce0b5e07086ec54e5a7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2cb6ae5dc92e4ce0b5e07086ec54e5a7
record_format	dspace
spelling	oai:doaj.org-article:2cb6ae5dc92e4ce0b5e07086ec54e5a72021-11-18T07:28:23ZNilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.1932-620310.1371/journal.pone.0030567https://doaj.org/article/2cb6ae5dc92e4ce0b5e07086ec54e5a72012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22348015/?tool=EBIhttps://doaj.org/toc/1932-6203We developed a xenograft model of human Chronic Eosinophilic Leukemia (CEL) to study disease progression and remission-induction under therapy with tyrosine kinase inhibitors using imatinib and nilotinib as examples. The FIP1L1/PDGFRA+ human CEL cell lineEOL-1 was injected intravenously into scid mice, and MR imaging and FACS analysis of mouse blood samples were performed to monitor disease development and the effects of imatinib and nilotinib. Organ infiltration was analyzed in detail by immunohistochemistry after sacrifice. All animals developed CEL and within one week of therapy, complete remissions were seen with both imatinib and nilotinib, resulting in reduced total tumor volumes by MR-imaging and almost complete disappearance of EOL-1 cells in the peripheral blood and in tissues. The new model system is feasible for the evaluation of new tyrosine kinase inhibitors and our data suggest that nilotinib may be a valuable additional targeted drug active in patients with FIP1L1/PDGFRA+ CEL.Daniel WickleinNuno Ramos LealJohannes SalamonMohammed ThamerHarald HerrmannPeter ValentUdo SchumacherSebastian UllrichPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 2, p e30567 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Daniel Wicklein Nuno Ramos Leal Johannes Salamon Mohammed Thamer Harald Herrmann Peter Valent Udo Schumacher Sebastian Ullrich Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.
description	We developed a xenograft model of human Chronic Eosinophilic Leukemia (CEL) to study disease progression and remission-induction under therapy with tyrosine kinase inhibitors using imatinib and nilotinib as examples. The FIP1L1/PDGFRA+ human CEL cell lineEOL-1 was injected intravenously into scid mice, and MR imaging and FACS analysis of mouse blood samples were performed to monitor disease development and the effects of imatinib and nilotinib. Organ infiltration was analyzed in detail by immunohistochemistry after sacrifice. All animals developed CEL and within one week of therapy, complete remissions were seen with both imatinib and nilotinib, resulting in reduced total tumor volumes by MR-imaging and almost complete disappearance of EOL-1 cells in the peripheral blood and in tissues. The new model system is feasible for the evaluation of new tyrosine kinase inhibitors and our data suggest that nilotinib may be a valuable additional targeted drug active in patients with FIP1L1/PDGFRA+ CEL.
format	article
author	Daniel Wicklein Nuno Ramos Leal Johannes Salamon Mohammed Thamer Harald Herrmann Peter Valent Udo Schumacher Sebastian Ullrich
author_facet	Daniel Wicklein Nuno Ramos Leal Johannes Salamon Mohammed Thamer Harald Herrmann Peter Valent Udo Schumacher Sebastian Ullrich
author_sort	Daniel Wicklein
title	Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.
title_short	Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.
title_full	Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.
title_fullStr	Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.
title_full_unstemmed	Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.
title_sort	nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/2cb6ae5dc92e4ce0b5e07086ec54e5a7
work_keys_str_mv	AT danielwicklein nilotinibandimatinibarecomparablyeffectiveinreducinggrowthofhumaneosinophilleukemiacellsinanewlyestablishedxenograftmodel AT nunoramosleal nilotinibandimatinibarecomparablyeffectiveinreducinggrowthofhumaneosinophilleukemiacellsinanewlyestablishedxenograftmodel AT johannessalamon nilotinibandimatinibarecomparablyeffectiveinreducinggrowthofhumaneosinophilleukemiacellsinanewlyestablishedxenograftmodel AT mohammedthamer nilotinibandimatinibarecomparablyeffectiveinreducinggrowthofhumaneosinophilleukemiacellsinanewlyestablishedxenograftmodel AT haraldherrmann nilotinibandimatinibarecomparablyeffectiveinreducinggrowthofhumaneosinophilleukemiacellsinanewlyestablishedxenograftmodel AT petervalent nilotinibandimatinibarecomparablyeffectiveinreducinggrowthofhumaneosinophilleukemiacellsinanewlyestablishedxenograftmodel AT udoschumacher nilotinibandimatinibarecomparablyeffectiveinreducinggrowthofhumaneosinophilleukemiacellsinanewlyestablishedxenograftmodel AT sebastianullrich nilotinibandimatinibarecomparablyeffectiveinreducinggrowthofhumaneosinophilleukemiacellsinanewlyestablishedxenograftmodel
_version_	1718423397905465344

Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.

Ejemplares similares